Regulamento sobre Avaliação das Tecnologias de Saúde e Grupo La Valetta

Heitor Costa, Director Executivo da APIFARMA

1 Cross-Country collaborations

• Historical ties (except Valetta) ⚑ Iceland BeneluxA • Countries move…

Finland Valetta Declaration ⚑ IE and LT belong to 2 CCC’s Norway ▼ Iberia partnership Sweden Estonia Visegrad+ • Not part of any CCC: Latvia Denmark⚑ FR, UK, DE and… BU, CH Baltic Partnership Lithuania Ireland Poland Nordic Council • North vs South/East Nordic Tendering pilot ⚑ Czech led by AMGROS Republic Slovakia FINOSE Hungary

▼ ▼

Cyprus 2 Cross-Country collaborations Nordic collaborations ⚑ Nordic tendering pilot (Denmark, Norway, Iceland) led by AMGROS ⚑ • September 2018: call for 2 off-patent Iceland products BeneluxA • Innovative medicines as a second iteration Finland not excluded Valetta Declaration ⚑ Norway • Combination of strong political will and ▼ Iberia partnership Sweden expertise Estonia Visegrad+ • Industry has been very active already Latvia locally (engagement, legal analysis…) Denmark⚑ Baltic Partnership Lithuania Ireland Poland Nordic Council Netherlands Nordic Tendering pilot ⚑ Belgium Czech ● FINOSE (Finland, Norway, Sweden) led by AMGROS Luxembourg Republic Slovakia FINOSE • Collaboration on HTA/REA Austria Hungary Slovenia Romania • High-level meeting on 27 March 2018 Italy Croatia • Evaluation of the initiative planned late 2020 ▼ ▼ • Actively reaching out to companies Portugal Spain Greece

Cyprus Malta 4 Cross-Country collaborations

⚑ Iceland BeneluxA

Finland Visegrad (V4+) Valetta Declaration ⚑ Norway • 2 March 2018 Bratislava meeting ▼ Iberia partnership Sweden • 2 competing companies invited, Estonia Visegrad+ originally to negotiate prices of their Latvia products Denmark⚑ Baltic Partnership Lithuania • Hungarian cabinet still committed; no Ireland Poland high-level political impetus yet since last Nordic Council Netherlands political reshuffle in April 2018 Nordic Tendering pilot • Legal framework reportedly competed ⚑ Belgium Czech led by AMGROS Luxembourg Republic Slovakia (June 2018) FINOSE nd Austria Hungary • Next round of discussion 2 half of Slovenia Romania September Italy Croatia

▼ ▼ Portugal Spain Greece

Cyprus Malta 5 Cross-Country collaborations

BeneluxA-I ⚑ • Ireland joined (22 June 2018) Iceland BeneluxA • Horizon Scanning • Call for tender announced (Sept. Finland Valetta Declaration ⚑ 2018) Norway • EFPIA-Pharma.be outreach (July ▼ Iberia partnership Sweden Estonia 2018) Visegrad+ • First positive reimbursement decision Latvia Denmark⚑ following joint price negotiation with Baltic Partnership Lithuania Ireland Belgium and Netherlands (11 July 2018) Poland • Other pilot joint-negotiations on-going Nordic Council Netherlands (expensive medicines) Nordic Tendering pilot ⚑ Belgium Czech • Reaching out to companies for joint led by AMGROS Luxembourg Republic Slovakia assessment FINOSE Austria Hungary Slovenia Romania Italy Croatia • www.beneluxa.org updated

▼ ▼ Portugal Spain Greece

Cyprus Malta 6 Beneluxa-I First pricing & reimbursement negotiation concluded

Common reimbursement conditions in Netherlands and Belgium announced on 12 July 2018 Joint HTA assessment Joint pricing negotiation Agreement concluded until end-2020 Manufacturer to collect Real World Evidence and carry out further research Question for other BeneluxA-I members, where the product is NOT reimbursed?

7 Cross-Country collaborations European Snapshot Nordic Tendering (Led by AMGROS) ⚑ • Pilot for joint tendering (Denmark, Norway, Iceland) to materialise in September 2018 – off-patent products • Innovative medicines as a second iteration not excluded

⚑ Baltic Partnership Iceland • Currently limited to joint tendering of vaccines BeneluxA

Finland Valetta Declaration ⚑ V4+ Norway • No known development since 2 March 2018 Bratislava ▼ Iberia partnership Sweden meeting Estonia • Hungarian cabinet still committed; no high-level political Visegrad+ impetus yet since last political reshuffle in April 2018 Latvia Denmark⚑ Baltic Partnership Lithuania Valetta Declaration Ireland • 3-4 May 2018 meeting in Lisbon – Croatia now a Poland member Nordic Council Netherlands • 11 July 2018 meeting in Athens (November meeting in Nordic Tendering pilot Bucharest) ⚑ Belgium Czech led by AMGROS Luxembourg Republic • 2 products reportedly under consideration Slovakia • Methodological issues under resolution FINOSE Austria Hungary Slovenia Romania BeneluxA Italy Croatia • Ireland joined - 22 June 2018 • Horizon Scanning: Call for tender announced Sept. 2018 ▼ ▼ • Reaching out to companies for joint assessment Portugal Spain Greece • First successful joint pricing negotiations BE-NL July 2018 Cyprus • www.beneluxa.org updated Malta 8 Cross-Country collaborations

⚑ Iceland BeneluxA Valetta Declaration • 3-4 May 2018 meeting in Lisbon Finland Valetta Declaration ⚑ • Croatia now a member Norway ▼ Iberia partnership Sweden • 11 July 2018 meeting in Athens Estonia • November meeting in Bucharest Visegrad+ • 2 products reportedly under consideration ⚑ Latvia Denmark • Methodological issues under resolution – Baltic Partnership Lithuania Ireland (legal framework) Poland Nordic Council Netherlands • Internal divergences among membership Nordic Tendering pilot ⚑ Belgium Czech led by AMGROS Luxembourg Republic Slovakia FINOSE Austria Hungary Slovenia Romania Italy Croatia

▼ ▼ Portugal Spain Greece

Cyprus Malta 9 Valetta Declaration 5th Meeting 10-11 July 2018, Athens

✱ Attendance • Ministers from Portugal, Romania, Greece, Cyprus, Malta + a secretary of state from Italy

• Valetta Technical Committee met in parallel ✱ MoH Xanthos reportedly made a proposal intending to address most gaps • International Convention

• Roadmap ✱ Bilateral cooperation between Cyprus and Greece considered (pricing) ✱ Non-alignment between members reported informally following the meeting ✱ Next meeting in Bucharest, Romania (November 2018)

10 Valetta Declaration Greece MoH Xanthos’ proposed next steps

✱ “International convention” to set a regulatory framework to "armour" the procedure in legal terms as well as the result of the negotiation; proposed • Clear process for horizon scanning and negotiations • Clear rules for transposition of decisions at national level • Impartiality and confidentiality ✱ Overcome companies' "unwillingness”, e.g. no parallel procedure ✱ Reinforce technical workstream (VTechnicalCommittee) ; better exchange of information (clinical trials, epidemiological data, target populations, comparable clinical evaluations etc.) ✱ Roadmap with ultimate target of common negotiation to overcome internal divergences and technical issues, e.g. maximum or minimum price, prices range or fixed price, ability or not to conduct negotiations at a national level after the conclusion of the procedure within the "Valletta").

11 VALETTA DEclaration Greek MoH Xanthos’ quote

“ We are forced to break the limits. "Valletta" can and must constitute the successful "example" of voluntary co-operation that will affect the present negative correlations in Europe in a catalytic manner (mainly to the opposition of Germany and the other countries, to any idea of common policies for Health and Medicinal products). We have nothing to lose, we do not have the luxury of the "loner course" against "coalitions of interests" with a huge financial and political influence, we are obligated to maintain a climate of high – and not least – expectations for the citizens of our countries. “

12 VALETTA Declaration Declarations following 5th Meeting 10-11 July 2018, Athens

Romania • Interest in access to innovative medicines, common mechanisms for MoH Sorina Pintea HTA and common negotiations. and State Secretary • Agreed on the need of having more relevant and tangible solutions, Octavian supported the Greek proposal Alexandrescu. • Availablity is a key RO EU presidency topic (from January 2018)

Malta “It is in our interest to collaborate since we face common problems, we face the same needs and therefore we can find common solutions through collaborating with the pharma industry – gaining a lot. The Greek proposal is important since it allows for processes acceleration.”

13 External Industry Public Policy Principles (July 2018)

Key principles ✱ Depending on circumstances, there might be instances where cross-country initiatives could improve patient access to medicines and others where the optimal outcome may be reached through national procedure; ✱ Industry would support the option that is bringing the optimal result in terms of timely and effective access to innovative treatments.

Positioning based on 5 key principles on:

✱ Horizon Scanning EFPIA/Industry 5 principles for collaboration (Dec. 2016)

✱ Joint Clinical Assessment and HTA 1. Broader & accelerated patient access ✱ Information Sharing and Price negotiations 2. No extra process burden (replace equivalent steps in countries) 3. For similar/close countries (economic/health/geographic) ✱ Public Procurement 4. Voluntary 5. Guaranted confidentiality

14 Overall Assessment Summary

European Commission Competition Commissioner Margrethe Vestager made a declaration supportive of joint negotiations at a WHO meeting on 20 August 2018. The EC organized with OECD support a ‘Workshop on Building Capacity for Pharmaceutical Negotiations in the EU’ on 19 October 2018.

BeneluxA-I The International Horizon Scanning Initiative (IHSI) is moving forward with 16 countries interested, and is to be granted legal personality under the form of a non- profit organisation by end-2018. IHSI will select a third party through tender by May 2019 to run the project.

Valetta The group has kept reaching out to companies for joint HTA assessment and joint pricing negotiations. Valetta members will meet on 26-27 November 2018 in Bucharest.

AMGROS-led tendering pilot The first joint tender between Denmark, Norway and Iceland was announced on 11 September 2018, for 11 off-patent products. Declarations from policy leaders confirm that the vision is to ultimately jointly tender patented products.

FINOSE A pharmaceutical company signed a letter of intent to file a product in the FINOSE framework.

Visegrad+ 4 countries are reportedly running a joint negotiation for an oncology product covering a ‘fairly large population’, according to Polish Deputy MoH Marcin Czech.

International Framework Agreement (Romania-Bulgaria) On 23 October 2018 the Romanian MoH declared its intention to implement the 2-year old agreement signed with Bulgaria in 2016 and that had not been ratified. The agreement requires both adoption by the 2 parliaments and a change of the legislation to become effective. 15 Overall Assessment Summary

Potential Opportunities Potential Challenges • Broaden overall access to therapies for patients • Unclear process: - Lack of governance and methodology to initiate, • Commercial opportunity by increasing market size conduct and conclude pilot projects and volume - No obligation for participating Member States to adopt the outcomes of joint reports • Harmonisation and streamlining of REA, HTA, • Unclear legal basis and framework in particular pricing negotiations, purchasing and contracting interactions with current EU (e.g. Transparency directive, public procurement legislation) and national processes – particularly beneficial for smaller legislations companies • Duplication and /or no consideration for existing pan- European initiatives (e.g. EUnetHTA, REA) • Workload sharing among authorities of participating • Limited of (successful) real-life experience (two pilots in Member States BeNeLuxA, one expected pilot in Nordic Council • Lack of clear impact of horizon scanning activities on • Support for better budgetary forecasts through budget forecasts horizon scanning • Risks of distortion in supply, trade and competition if no appropriate conditions for purchasing and contracting • Opportunity to broaden collaboration beyond price (e.g. sound tender criteria) (e.g focusing on joint patient registries, early diagnosis) 16 MS posi ons based on latest intelligence (23.10.18) Disclaimer: Influence in This is a subjec ve Council DE interpreta on

FR of various intel AT RO NL IT

DK BE ES

PL PT

IE

EL

SK

BU SE HU HR

FI

LT

SI UK EE

CZ CY

LUX LV

MT

No duplica on BUT No duplica on BUT Full integra on & re4p lacement Fully voluntary (ie duplica on) Na onal complements at MS discre on Na onal complements with legally EC Proposal 17 DE/FR non-paper Likely discussion in Council enforceable safeguards EP text with legal check